Quibim SL

Logo Quibim

Logo Quibim

Contact information

Quibim SL
Ana Blanco Sánchez, Grants and Innovation Coordinator
Avenida Aragon 30, Planta 13, Oficina I - J
+34 96 124 32 25
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biomarkers
      • Diagnostic imaging
      • Medical devices
    • Therapeutic areas
      • Oncology
  • D. Services
    • R&D services
      • Internet and information technologies

Quibim is a company designing and creating pioneering tools that unlock imaging data to maximize drug programmes and improve patient outcomes. The company follows an AI-first approach to help detect pathologies and predict outcomes in oncology/immunotherapy, rheumatology and neurology using imaging modalities such as MRI, CT and PET. The goal of the company is to transform imaging into actionable predictions.

Products and services

Quibim is specialized in big imaging infrastructures to advance the development of AI models and help real-world evidence (RWE) and biopharma partners extract new insights from images. Quibim develops novel quantitative imaging biomarkers to deeply analyze disease mechanisms, advancing in drug discovery and monitoring treatment progress through a whole-body approach, offering one ecosystem with several suites focused on the following systems: central nervous, musculoskeletal, male and female reproductive, gastro-intestinal and respiratory. Using the power and promise of quantified imaging data and AI, Quibim wants to turn imaging into a catalyst of precision health.

Quibim Precision® platform (CE Mark) is an image processing software package that can be used to perform image viewing, processing and analysis of medical images. The platform integrates different whole-body analysis modules that allows the automated characterization and quantification. Specifically, the product QP-Prostate, Quibim’s AI-based prostate cancer diagnosis solution, is an FDA(510k) cleared prostate MR images processing and quantitative analysis software package that runs automatically and streamlines the process while adding value to clinicians. 

Areas of interest for future collaborations

Our strategic lines are:

  1. Partnering life sciences and RWE companies to develop novel predictive models of key challenges in healthcare;
  2. Lead the evidence generation from big repositories of real-world imaging data;
  3. Combine the solutions identified in (1) and the insights extracted in (2) to design and create best-in-class medical devices for the market.

The creation of collaborations/partnerships to advance in any of the lines described above would be of great interest to Quibim since they would allow the clinical adoption of AI-based models to be increasingly closer, achieving precision medicine that enhances the quality of life of patients.